Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for Eosinophilic Fasciitis
NCT04305678Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of mepolizumab in eosinophilic fasciitis (EF), sponsored by Mayo Clinic. Primary endpoint: Modified Rodnan Skin Score at 24 weeks. Planned start Feb 2023; status: withdrawn.
02
Drugs
mepolizumab
03
Conditions
eosinophilic fasciitis (EF)
Beyond the preview
Go deeper on NCT04305678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305678.